Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for GLEEVEC
- Imatinib TDM in GIST
- Effect of Imatinib in Advance Liver Fibrosis Patients
- Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
- PLATFORM Study of Precision Medicine for Rare Tumors
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
- Entacapone Combination With Imatinib for Treatment of GIST
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
- A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
- LAM Pilot Study With Imatinib Mesylate
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML
- Pioglityazone and Imatinib for CML Patients
- Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
- Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
- Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy
- Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
- Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
- A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
- Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
- to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers
- TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
- Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
- A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
- Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
- Ipilimumab and Imatinib Mesylate in Advanced Cancer
- Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
- Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
- Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
- Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
- Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
- A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
- Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
- Drug-drug Interaction Study With Metformin and Imatinib
- Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
- Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
- Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
- Imatinib in KIT-negative Systemic Mastocytosis
- A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
- A Global Imatinib and Nilotinib Pregnancy Exposure Registry
- Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
- Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
- Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
- A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
- RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
- Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
- Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
- Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
- A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
- Treatment of Polycythemia Vera With Gleevec
- Late Chronic Phase Chronic Myelogenous Leukemia
- Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
- Evaluation of Patients With Bulky GIST Using Sunitinib
- GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
- Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
- Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
- Autologous Transplantation for Chronic Myelogenous Leukemia
- CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
- XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
- Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis
- Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
- New Individualized Therapy Trial for Metastatic Colorectal Cancer
- Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
- Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
- Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
- Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
- Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
- Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers
- Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
- Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
- Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
- Study of Temzolomide and Gleevec in Advanced Melanoma
- Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
- Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
- A Phase I/Expansion Study of Dasatinib
- A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
- Safety Study of Gleevec® in Children With Pulmonary Hypertension
- Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
- Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
- Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients
- Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
- An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
- Reduced Intensity AlloSCT in(CML) With Persistent Disease
- Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
- A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
- Gleevec Study for Patients With Ovarian Cancer
- Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
- Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
- Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
- Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
- Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
- Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
- Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
- Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
- Ph II Study of Perifosine Plus Gleevec for Patients With GIST
- Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
- Effect of Antacids on Gleevec® in Healthy Volunteers
- Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
- Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers
- Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
- Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
- Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
- TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
- Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
- Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
- Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
- Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
- Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
- PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
- Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
- Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
- Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
- Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children
- Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
- Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
- A Study of Imatinib and Docetaxel in Prostate Cancer
- A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
- Imatinib Mesylate in Treating Patients With Myelofibrosis
- Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
- Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
- Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
- Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
- Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma
- Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
- Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
- Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
- Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
- Glivec Phase II Pediatric Study
- Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
- Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia
- A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
- Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
- Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
- Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
- Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
- PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
- Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
- Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
- Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
- Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
- BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
- Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
- Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
- PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
- S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
- Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
- Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
- Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
- Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
- Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
- A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
- Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
- S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
- A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
- Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
- Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
- Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
- AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
- Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
- Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
- Therapy of Early Chronic Phase CML With Gleevec
- Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
- Imatinib Mesylate in Treating Patients With Recurrent Meningioma
- Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
- Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
- Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
- Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
- Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
- Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
- Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
- Imatinib Mesylate in Treating Patients With Myelofibrosis
- Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
- Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
- Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
- Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
- Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
- Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, D
- Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
- Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
- Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
- Imatinib Mesylate in Treating Patients With Metastatic Melanoma
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
- Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
- STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Clinical trials list
click for details